InPedILD_trial_enrollment InPedILD_trial_enrollment First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Empowering smallholder farmers Empowering smallholder farmers The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
The chronic nature of generalized pustular psoriasis The chronic nature of generalized pustular psoriasis Understanding the impact of the physical and psychological symptoms of this chronic disease.
Cystic Fibrosis Genetherapy Development Option Excercise Cystic Fibrosis Genetherapy Development Option Excercise Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
reduced-heart-failure-treatment-approval-europe reduced-heart-failure-treatment-approval-europe European approval for treatment of adults with heart failure with reduced ejection fraction
Ukraine Help: We fly, we bike, we accommodate Ukraine Help: We fly, we bike, we accommodate The solidarity for Ukraine from Boehringer Ingelheim employees is incredible. Equally impressive is their practical help.
The status of schizophrenia care The status of schizophrenia care A closer look at the status of the schizophrenia care landscape, an often misunderstood mental health condition
Imagine: The impact of volunteering activities on elderly well-being Imagine: The impact of volunteering activities on elderly well-being How our employees contribute to elderly well-being with creative volunteering activities in Australia, South Korea, Southeast Asia, and New Zealand.
Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Why is Diversity, Equity and Inclusion important to us? Why is Diversity, Equity and Inclusion important to us? Why is Diversity, Equity and Inclusion important to us?
Investigational treatment slowed lung function decline in IPF Investigational treatment slowed lung function decline in IPF Investigational treatment slowed lung function decline in IPF
BTD for GlyT1 in Schizophrenia BTD for GlyT1 in Schizophrenia Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
LastMile initiative to address barriers in animal healthcare LastMile initiative to address barriers in animal healthcare The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African
discontinuation-bi-1467335-diabetic-retinopathy discontinuation-bi-1467335-diabetic-retinopathy The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Arti-cell Forte stem cell-based veterinary product Arti-cell Forte stem cell-based veterinary product Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved FDA- HFpEF-breakthrough-designation-EMPEROR-preserved U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
preserved-heart-failure-treatment-FDA-US-approval preserved-heart-failure-treatment-FDA-US-approval US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
emperor-preserved-heart-failure-toplineresults emperor-preserved-heart-failure-toplineresults Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
emperor-reduced-chmp-positive-opinion emperor-reduced-chmp-positive-opinion CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
Innovation from within Innovation from within Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Collaboration-with-OxfordBioTherapeutics Collaboration-with-OxfordBioTherapeutics Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Fight against COVID-19 pandemic Fight against COVID-19 pandemic Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
10 things you should know about rabies 10 things you should know about rabies 10 things you should know about rabies
1948-1990: Going global 1948-1990: Going global The Boehringer Ingelheim history from 1948-1990, with milestones